Evidence & concentration worksheet · Longevity & Mitochondrial Health
SS-31 30 mg
Evidence supports named, regulated products and indications. A research powder or different vial strength does not inherit the approved product's formulation, reconstitution, storage, or dosing instructions.
Evidence review
Approved dosing is product-specific
Evidence supports named, regulated products and indications. A research powder or different vial strength does not inherit the approved product's formulation, reconstitution, storage, or dosing instructions.
How it works
SS-31, also called elamipretide, is a mitochondria-targeted tetrapeptide. In September 2025 FDA granted accelerated approval to the prescription product Forzinity (elamipretide). That approval is narrow and product-specific; it does not apply to generic “SS-31” research vials, wellness use, or other mitochondrial disorders.[1]
Benefits & side effects
In the 218-participant MMPOWER-3 trial, elamipretide did not improve the six-minute walk distance or fatigue at 24 weeks in primary mitochondrial myopathy.[4] In the much smaller 12-person randomized Barth syndrome crossover trial, neither primary endpoint was met during the blinded phase; improvements appeared during the open-label extension.[5]
These mixed, disease-specific results show why an approval for Barth syndrome cannot be reframed as evidence for energy, exercise performance, anti-aging, recovery, heart disease, or general mitochondrial support.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- U.S. FDA — FDA grants accelerated approval to first treatment for Barth syndrome (2025)
- DailyMed — Forzinity (elamipretide) official prescribing information (2025)
- U.S. FDA — Ongoing non-malignant accelerated approvals (2026)
- Neurology — MMPOWER-3 randomized clinical trial (2023)
- Genetics in Medicine — Randomized trial and open-label extension in Barth syndrome (2021)
Other vial sizes